Biomarker zur Frühdiagnose des idiopathischen Parkinson-Syndroms

Zusammenfassung

Zum Zeitpunkt der Manifestation motorischer Symptome des idiopathischen Parkinson-Syndroms besteht bereits ein signifikanter Verlust dopaminerger Neurone in der Substantia nigra. Zur Identifikation unspezifischer nichtmotorischer Symptome im Frühstadium des idiopathischen Parkinson-Syndroms wurden in den vergangenen Jahren verschiedene bildgebende, klinische und biochemische Methoden entwickelt. Die Etablierung von Biomarkern, die die progrediente Neurodegeneration objektiv erfassen, ist im Hinblick auf eine zukünftige potenziell neuroprotektive Therapie von hohem wissenschaftlichen und klinischen Interesse.

Summary

By the time a clinical diagnosis of Parkinson’s disease is made, a significant loss of mesencephalic dopaminergic neurons has already occured. Identifying patients in the preclinical period early diagnostic strategies such as neuroimaging techniques, clinical and biochemical methods have been developed during the last few years. The establishment of biomarkers that can faithfully measure dopaminergic neuron loss is of high preclinical and clinical interest especially in the light of the development of potential neuroprotective therapy.

Schlüsselwörter

Idiopathisches Parkinson-Syndrom - Frühdiagnostik - Frühsymptome - präklinische Phase

Keywords

Parkinson’s disease - early diagnosis - early symptoms - pre-clinical phase

^* Beide Autorinnen waren in gleichem Maße an der Erstellung dieser Arbeit beteiligt.

• Literatur

• 1 Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chron Dis 1975; 28: 493-7.
• 2 Becker G, Seufert J, Bogdahn U. et al. Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 1995; 45: 182-84.
• 3 Benamer TS, Patterson J, Grosset DG. et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503-10.
• 4 Berendse HW. et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol 2001; 50: 34-41.
• 5 Berg D. et al. Vulnerability of the nigro-striatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-31.
• 6 Berg D, Roggendorf W, Schröder U. et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
• 7 Berg D, Stiefker C, Becker G. Echogenity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 2001; 8: 684-9
• 8 Bodis-Wollner I, Marx MS, Mitra S. et al. Visual dysfunction in Parkinson’s disease. Loss in spatiotemporal contrast sensitivity. Brain 1987; 110: 1675-98.
• 9 Burn DJ, Mark MH, Playford ED. et al. Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894-1900.
• 10 Buttner T. et al. L-Dopa improves colour vision in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 1994; 7: 13-9.
• 11 Buttner T. et al. Distorted color discrimination in ‘de novo’ parkinsonian patients. Neurology 1995; 45: 386-7.
• 12 Ceballos-Baumann AO, Lemke MR. Parkinson-Syndrom und Depression. Nervenheilkunde 2004; 23: 143-50.
• 13 Chouker M, Tatsch K, Linke R. et al. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001; 22: 721-5.
• 14 Dexter DT, Wells FR, Lees AJ. et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989; 52: 1830-6.
• 15 Doty RL. et al. Olfactory dysfunction in Parkinson’s disease: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-44.
• 16 Double KL, Gerlach M, Youdim MB. et al. Impaired iron homeostasis in Parkinson’s disease. J Neural Transm Suppl 2000: 37-58.
• 17 Double K, Rowe DB, Halliday GM. et al. A biochemical test to diagnose Parkinson’s disease. J Neural Transm 2002; 109 (Suppl): III.
• 18 Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997; 244: 2-8.
• 19 Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-46.
• 20 Hummel T. et al. Kallmann’s syndrome and chemosensory evoked potentials. Eur Arch Otorhinolaryngol 1991; 248: 311-2.
• 21 Jennings DL. et al. (123I)-beta-CIT and singlephoton emission computertomographic imaging vs clinical evaluation in Parkinson syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61 (08) 1224-9.
• 22 Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17: 417-23.
• 23 Kitada T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
• 24 Louis ED, Jurewicz EC. Olfaction in essential tremor patients with and without isolated rest tremor. Mov Disord 2003; 18: 1387-9.
• 25 Marek KL, Seibyl JP, Zoghbi SS. et al. ¹²³I-beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996; 46: 231-7.
• 26 Matheson JK, Clifford BS. REM sleep behavior disorder a dopaminegic deficiency disorder?. Neurology 2003; 61: 1328-1329
• 27 Michell AW, Luheshi L, Fritz D. et al. Peripheral biomarkers of Parkinson’s disease. Mov Disord 2004; 19: S279 P796.
• 28 Muller A, Abolmaali N, Hummel T, Reichmann H. Riechstörungen – ein frühes Kardinalsymptom des idiopathischen Parkinson-Syndroms. Akt Neurol 2003; 30: 239-43.
• 29 Muller A. et al. Olfactory function in idiopathic Parkinson’s disease (IPD): results from crosssectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-11.
• 30 Montgomery Jr EB. et al. Early detection of probable idiopathic Parkinson’s disease: I. Development of a diagnostic test battery. Mov Disord 2000; 15: 467-73.
• 31 Pirker W, Djamshidian S, Asenbaum S. et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal βCIT-SPECT study. Mov Disord 2002; 17: 45-53.
• 32 Poewe W, Luginger E. Depression in Parkinson’s disease: impediments to recognition and treatment options. Neurology 1999; 52 (Suppl. 03) S2-6.
• 33 Polymeropoulos MH, Lavedan C, Leroy E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045-7.
• 34 Riederer P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515-20.
• 35 Ruprecht-Dorfler P, Berg D, Tucha O. et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 2003; 18: 416-22.
• 36 Santamaria J. et al. Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-3.
• 37 Schenk CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep disorder. Neurology 1996; 46: 388-93.
• 38 Schwarz J, Tatsch K, Arnold G. et al. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42: 556-61.
• 39 Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. J Nucl Med 1996; 37: 1112-5.
• 40 Sommer U. et al. Detection of presymptomatic Parkinson’s disease: Combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-202.
• 41 Sofic E, Riederer P, Heinsen H. et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199-205.
• 42 Walter U. et al. Substantia nigra echogenity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J Neural Transm 2002; 109: 191-6.
• 43 Walter U, Niehaus L, Probst T. et al. Brain parenchyma sonography discrimiates Parkinson’s disease and atypical parkinsonian syndroms. Neurology 2003; 60: 74-7.
• 44 Walter U, Klein C, Hilker R. et al. Brain parenchyma sonographie detects preclinical parkinsonism. Mov Disord. 2004 in press.
• 45 Wenning GK. et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-50.
• 46 Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004; 108: 17-40.
• 47 Wolters EC. et al. Preclinical (premotor) Parkinson’s disease. J Neurol 2000; 247 (Suppl. 02) II103-9.